Sharecafe

Radiopharm Theranostics (ASX:RAD) to start prostate cancer trial

Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company's portfolio of therapies.

Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company’s portfolio of therapies.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories